{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T22:43:20Z","timestamp":1790462600667,"version":"4.1.0"},"reference-count":199,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.lfs.2020.117883","type":"journal-article","created":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T15:43:44Z","timestamp":1591026224000},"page":"117883","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":110,"special_numbering":"C","title":["Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements"],"prefix":"10.1016","volume":"256","author":[{"given":"Abhjieet","family":"Pandey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajinkya Nitin","family":"Nikam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajjappla Basavaraj","family":"Shreya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadhana P.","family":"Mutalik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Gopalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharath Singh","family":"Padya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gasper","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas","family":"Mutalik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Prassl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2020.117883_bb0005","series-title":"Clinical Virology","author":"Richman","year":"2016"},{"issue":"8 Suppl","key":"10.1016\/j.lfs.2020.117883_bb0010","first-page":"S9","article-title":"SARS: epidemiology","author":"Chan-Yeung","year":"2003","journal-title":"Respirology"},{"key":"10.1016\/j.lfs.2020.117883_bb0015","author":"W.H. Organization"},{"key":"10.1016\/j.lfs.2020.117883_bb0020","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/cr.2013.92","article-title":"Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4","volume":"23","author":"Wang","year":"2013","journal-title":"Cell Res."},{"key":"10.1016\/j.lfs.2020.117883_bb0025","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/resp.13196","article-title":"MERS, SARS and other coronaviruses as causes of pneumonia","volume":"23","author":"Yin","year":"2018","journal-title":"Respirology"},{"key":"10.1016\/j.lfs.2020.117883_bb0030","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(03)14630-2","article-title":"Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People\u2019s Republic of China, in February, 2003","volume":"362","author":"Zhong","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2020.117883_bb0035","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2020.117883_bb0040","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2020.117883_bb0045","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41579-018-0118-9","article-title":"Origin and evolution of pathogenic coronaviruses","volume":"17","author":"Cui","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.lfs.2020.117883_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105924","article-title":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges","volume":"55","author":"Lai","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.lfs.2020.117883_bb0055","series-title":"Laboratory Testing for Coronavirus Disease 2019 (COVID-19) in Suspected Human Cases: Interim Guidance, 2 March 2020","author":"W.H. Organization","year":"2020"},{"key":"10.1016\/j.lfs.2020.117883_bb0060","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taaa021","article-title":"The reproductive number of COVID-19 is higher compared to SARS coronavirus","volume":"27","author":"Liu","year":"2020","journal-title":"J Travel Med"},{"key":"10.1016\/j.lfs.2020.117883_bb0065","unstructured":"Coronavirus (COVID-19) events as they happen, (n.d.). https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/events-as-they-happen (accessed April 10, 2020)."},{"key":"10.1016\/j.lfs.2020.117883_bb0070","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.chom.2020.02.001","article-title":"Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China","volume":"27","author":"Wu","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.lfs.2020.117883_bb0075","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2020.117883_bb0080","article-title":"Genotype and phenotype of COVID-19: their roles in pathogenesis","author":"Mousavizadeh","year":"2020","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"10.1016\/j.lfs.2020.117883_bb0085","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00127-20","article-title":"Receptor recognition by the novel coronavirus from wuhan: an analysis based on decade-long structural studies of SARS coronavirus","volume":"94","author":"Wan","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.lfs.2020.117883_bb0090","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2020.117883_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105951","article-title":"Coronavirus disease 2019 (COVID-19): current status and future perspectives","author":"Li","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.lfs.2020.117883_bb0100","doi-asserted-by":"crossref","unstructured":"Severe outcomes among patients with coronavirus disease 2019 (COVID-19) \u2014 United States, February 12\u2013March 16, 2020 | MMWR, (n.d.). https:\/\/www.cdc.gov\/mmwr\/volumes\/69\/wr\/mm6912e2.htm (accessed April 10, 2020).","DOI":"10.15585\/mmwr.mm6912e2"},{"key":"10.1016\/j.lfs.2020.117883_bb0105","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2020.117883_bb0110","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.3346\/jkms.2015.30.12.1807","article-title":"Renal complications and their prognosis in korean patients with middle east respiratory syndrome-coronavirus from the central MERS-CoV designated hospital","volume":"30","author":"Cha","year":"2015","journal-title":"J. Korean Med. Sci."},{"key":"10.1016\/j.lfs.2020.117883_bb0115","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/S0140-6736(03)13412-5","article-title":"Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study","volume":"361","author":"Peiris","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2020.117883_bb0120","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1056\/NEJMc2001737","article-title":"SARS-CoV-2 viral load in upper respiratory specimens of infected patients","volume":"382","author":"Zou","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2020.117883_bb0125","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1073\/pnas.0805270106","article-title":"Cryo-electron tomography of mouse hepatitis virus: insights into the structure of the coronavirion","volume":"106","author":"B\u00e1rcena","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lfs.2020.117883_bb0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0064013","article-title":"Identifying SARS-CoV membrane protein amino acid residues linked to virus-like particle assembly","volume":"8","author":"Tseng","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2020.117883_bb0135","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12985-019-1182-0","article-title":"Coronavirus envelope protein: current knowledge","volume":"16","author":"Schoeman","year":"2019","journal-title":"Virol. J."},{"key":"10.1016\/j.lfs.2020.117883_bb0140","series-title":"Roles of Host Gene and Non-coding RNA Expression in Virus Infection","first-page":"1","article-title":"Host factors in coronavirus replication","author":"de Wilde","year":"2018"},{"key":"10.1016\/j.lfs.2020.117883_bb0145","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.1128\/JVI.79.9.5288-5295.2005","article-title":"Identification of novel subgenomic RNAs and noncanonical transcription initiation signals of severe acute respiratory syndrome coronavirus","volume":"79","author":"Hussain","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.lfs.2020.117883_bb0150","doi-asserted-by":"crossref","first-page":"14406","DOI":"10.1074\/jbc.RA119.008964","article-title":"The C-terminal domain of the MERS coronavirus M protein contains a trans-Golgi network localization signal","volume":"294","author":"Perrier","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lfs.2020.117883_bb0155","series-title":"Coronavirus Replication and Reverse Genetics","first-page":"31","article-title":"Coronavirus transcription: a perspective","author":"Sawicki","year":"2005"},{"key":"10.1016\/j.lfs.2020.117883_bb0160","first-page":"1","article-title":"Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein","author":"Xia","year":"2020","journal-title":"Cellular & Molecular Immunology"},{"key":"10.1016\/j.lfs.2020.117883_bb0165","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.micinf.2020.01.003","article-title":"Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China","volume":"22","author":"Yu","year":"2020","journal-title":"Microbes Infect."},{"key":"10.1016\/j.lfs.2020.117883_bb0170","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1586\/14760584.2014.912134","article-title":"Current advancements and potential strategies in the development of MERS-CoV vaccines","volume":"13","author":"Zhang","year":"2014","journal-title":"Expert Review of Vaccines"},{"key":"10.1016\/j.lfs.2020.117883_bb0175","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/22221751.2020.1719902","article-title":"Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan","volume":"9","author":"Chan","year":"2020","journal-title":"Emerging Microbes & Infections"},{"key":"10.1016\/j.lfs.2020.117883_bb0180","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1146\/annurev-virology-100114-055218","article-title":"Continuous and discontinuous RNA synthesis in coronaviruses","volume":"2","author":"Sola","year":"2015","journal-title":"Annu Rev Virol"},{"key":"10.1016\/j.lfs.2020.117883_bb0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005473","article-title":"High-resolution analysis of coronavirus gene expression by RNA sequencing and ribosome profiling","volume":"12","author":"Irigoyen","year":"2016","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.lfs.2020.117883_bb0190","doi-asserted-by":"crossref","unstructured":"R. Rangan, I.N. Zheludev, R. Das, RNA Genome Conservation and Secondary Structure in SARS-CoV-2 and SARS-related Viruses, BioRxiv. (2020) 2020.03.27.012906. doi:https:\/\/doi.org\/10.1101\/2020.03.27.012906.","DOI":"10.1101\/2020.03.27.012906"},{"key":"10.1016\/j.lfs.2020.117883_bb0195","doi-asserted-by":"crossref","unstructured":"D.E. Gordon, G.M. Jang, M. Bouhaddou, J. Xu, K. Obernier, M.J. O'Meara, J.Z. Guo, D.L. Swaney, T.A. Tummino, R. Huettenhain, R.M. Kaake, A.L. Richards, B. Tutuncuoglu, H. Foussard, J. Batra, K. Haas, M. Modak, M. Kim, P. Haas, B.J. Polacco, H. Braberg, J.M. Fabius, M. Eckhardt, M. Soucheray, M.J. Bennett, M. Cakir, M.J. McGregor, Q. Li, Z.Z.C. Naing, Y. Zhou, S. Peng, I.T. Kirby, J.E. Melnyk, J.S. Chorba, K. Lou, S.A. Dai, W. Shen, Y. Shi, Z. Zhang, I. Barrio-Hernandez, D. Memon, C. Hernandez-Armenta, C.J.P. Mathy, T. Perica, K.B. Pilla, S.J. Ganesan, D.J. Saltzberg, R. Ramachandran, X. Liu, S.B. Rosenthal, L. Calviello, S. Venkataramanan, J. Liboy-Lugo, Y. Lin, S.A. Wankowicz, M. Bohn, P.P. Sharp, R. Trenker, J.M. Young, D.A. Cavero, J. Hiatt, T.L. Roth, U. Rathore, A. Subramanian, J. Noack, M. Hubert, F. Roesch, T. Vallet, B. Meyer, K.M. White, L. Miorin, O.S. Rosenberg, K.A. Verba, D. Agard, M. Ott, M. Emerman, D. Ruggero, A. Garc\u00eda-Sastre, N. Jura, M. von Zastrow, J. Taunton, A. Ashworth, O. Schwartz, M. Vignuzzi, C. d'Enfert, S. Mukherjee, M. Jacobson, H.S. Malik, D.G. Fujimori, T. Ideker, C.S. Craik, S. Floor, J.S. Fraser, J. Gross, A. Sali, T. Kortemme, P. Beltrao, K. Shokat, B.K. Shoichet, N.J. Krogan, A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-repurposing, BioRxiv. (2020) 2020.03.22.002386. doi:https:\/\/doi.org\/10.1101\/2020.03.22.002386.","DOI":"10.1038\/s41586-020-2286-9"},{"key":"10.1016\/j.lfs.2020.117883_bb0200","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1146\/annurev-virology-110615-042301","article-title":"Structure, function, and evolution of coronavirus spike proteins","volume":"3","author":"Li","year":"2016","journal-title":"Annu Rev Virol"},{"key":"10.1016\/j.lfs.2020.117883_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.lfs.2020.117883_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.lfs.2020.117883_bb0215","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.lfs.2020.117883_bb0220","doi-asserted-by":"crossref","DOI":"10.3390\/v11100972","article-title":"The S2 subunit of QX-type infectious bronchitis coronavirus spike protein is an essential determinant of neurotropism","volume":"11","author":"Cheng","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.lfs.2020.117883_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104742","article-title":"The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade","volume":"176","author":"Coutard","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.lfs.2020.117883_bb0230","first-page":"1","article-title":"SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion","author":"Wang","year":"2020","journal-title":"Cellular & Molecular Immunology"},{"key":"10.1016\/j.lfs.2020.117883_bb0235","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41422-020-0305-x","article-title":"Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion","volume":"30","author":"Xia","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.lfs.2020.117883_bb0240","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s13238-011-1034-1","article-title":"Activation and maturation of SARS-CoV main protease","volume":"2","author":"Xia","year":"2011","journal-title":"Protein Cell"},{"key":"10.1016\/j.lfs.2020.117883_bb0245","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.lfs.2020.117883_bb0250","doi-asserted-by":"crossref","first-page":"E3900","DOI":"10.1073\/pnas.1323705111","article-title":"One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities","volume":"111","author":"Subissi","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lfs.2020.117883_bb0255","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.febslet.2004.08.015","article-title":"Evaluation of metal-conjugated compounds as inhibitors of 3CL protease of SARS-CoV","volume":"574","author":"Hsu","year":"2004","journal-title":"FEBS Lett."},{"key":"10.1016\/j.lfs.2020.117883_bb0260","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.femsim.2004.11.004","article-title":"Interaction of viral proteins with metal ions: role in maintaining the structure and functions of viruses","volume":"43","author":"Chaturvedi","year":"2005","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"10.1016\/j.lfs.2020.117883_bb0265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1001176","article-title":"Zn2+ inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture","volume":"6","author":"te Velthuis","year":"2010","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.lfs.2020.117883_bb0270","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1039\/b709515e","article-title":"Inhibition of SARS coronavirus helicase by bismuth complexes","author":"Yang","year":"2007","journal-title":"Chem. Commun."},{"key":"10.1016\/j.lfs.2020.117883_bb0275","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.7150\/ijbs.45498","article-title":"Targeting the endocytic pathway and autophagy process as a novel therapeutic strategy in COVID-19","volume":"16","author":"Yang","year":"2020","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.lfs.2020.117883_bb0280","series-title":"StatPearls","article-title":"Features, evaluation and treatment coronavirus (COVID-19)","author":"Cascella","year":"2020"},{"key":"10.1016\/j.lfs.2020.117883_bb0285","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/d41573-020-00016-0","article-title":"Therapeutic options for the 2019 novel coronavirus (2019-nCoV)","volume":"19","author":"Li","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.lfs.2020.117883_bb0290","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.lfs.2020.117883_bb0295","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/17460441.2020.1704729","article-title":"Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics","volume":"15","author":"Talevi","year":"2020","journal-title":"Expert Opin. Drug Discovery"},{"key":"10.1016\/j.lfs.2020.117883_bb0300","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.lfs.2020.117883_bb0305","first-page":"61","article-title":"Drug repurposing from an academic perspective","volume":"8","author":"Oprea","year":"2011","journal-title":"Drug Discovery Today: Therapeutic Strategies"},{"key":"10.1016\/j.lfs.2020.117883_bb0310","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1473-3099(06)70361-9","article-title":"New insights into the antiviral effects of chloroquine","volume":"6","author":"Savarino","year":"2006","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.lfs.2020.117883_bb0315","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/cr.2012.165","article-title":"Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model","volume":"23","author":"Yan","year":"2013","journal-title":"Cell Res."},{"key":"10.1016\/j.lfs.2020.117883_bb0320","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1743-422X-2-69","article-title":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread","volume":"2","author":"Vincent","year":"2005","journal-title":"Virol. J."},{"key":"10.1016\/j.lfs.2020.117883_bb0325","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.lfs.2020.117883_bb0330","unstructured":"Chinese Clinical Trial Register (ChiCTR) - The world health organization international clinical trials registered organization registered platform, (n.d.). http:\/\/www.chictr.org.cn\/showprojen.aspx?proj=49145 (accessed April 8, 2020)."},{"key":"10.1016\/j.lfs.2020.117883_bb0335","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"Gao","year":"2020","journal-title":"Biosci Trends"},{"key":"10.1016\/j.lfs.2020.117883_bb0340","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1021\/jm0601856","article-title":"Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities","volume":"49","author":"Biot","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.lfs.2020.117883_bb0345","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","article-title":"American academy of ophthalmology, recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision)","volume":"123","author":"Marmor","year":"2016","journal-title":"Ophthalmology."},{"key":"10.1016\/j.lfs.2020.117883_bb0350","doi-asserted-by":"crossref","unstructured":"D. Zhou, S.-M. Dai, Q. Tong, COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression, J. Antimicrob. Chemother.. (n.d.). doi:https:\/\/doi.org\/10.1093\/jac\/dkaa114.","DOI":"10.1093\/jac\/dkaa114"},{"key":"10.1016\/j.lfs.2020.117883_bb0355","series-title":"Hydroxychloroquine and Azithromycin as a Treatment of COVID-19: Preliminary Results of an Open-label Non-randomized Clinical Trial","author":"Gautret","year":"2020"},{"key":"10.1016\/j.lfs.2020.117883_bb0360","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrd.2015.37","article-title":"Coronaviruses \u2014 drug discovery and therapeutic options","volume":"15","author":"Zumla","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.lfs.2020.117883_bb0365","series-title":"Clinical Characteristics of 51 Patients Discharged From Hospital With COVID-19 in Chongqing, China","author":"Lei","year":"2020"},{"key":"10.1016\/j.lfs.2020.117883_bb0370","article-title":"Case of the index patient who caused tertiary transmission of coronavirus disease 2019 in Korea: the application of lopinavir\/ritonavir for the treatment of COVID-19 pneumonia monitored by quantitative RT-PCR","volume":"35","author":"Lim","year":"2020","journal-title":"J. Korean Med. Sci."},{"key":"10.1016\/j.lfs.2020.117883_bb0375","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41579-019-0233-2","article-title":"Therapeutic strategies to target the Ebola virus life cycle","volume":"17","author":"Hoenen","year":"2019","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.lfs.2020.117883_bb0380","doi-asserted-by":"crossref","first-page":"eaau9242","DOI":"10.1126\/scitranslmed.aau9242","article-title":"Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge","volume":"11","author":"Lo","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.lfs.2020.117883_bb0385","doi-asserted-by":"crossref","DOI":"10.1002\/phar.2398","article-title":"Review of emerging pharmacotherapy for the treatment of coronavirus disease 2019","author":"Barlow","year":"2020","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.lfs.2020.117883_bb0390","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-13940-6","article-title":"Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV","volume":"11","author":"Sheahan","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.lfs.2020.117883_bb0395","doi-asserted-by":"crossref","first-page":"eaal3653","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.lfs.2020.117883_bb0400","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2020.117883_bb0405","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s40262-015-0364-1","article-title":"Ebola virus infection: review of the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials","volume":"55","author":"Madelain","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.lfs.2020.117883_bb0410","unstructured":"Severe 2019-nCoV Remdesivir RCT - full text view - ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04257656 (accessed April 9, 2020)."},{"key":"10.1016\/j.lfs.2020.117883_bb0415","unstructured":"Mild\/moderate 2019-nCoV Remdesivir RCT - full text view - ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04252664 (accessed April 9, 2020)."},{"key":"10.1016\/j.lfs.2020.117883_bb0420","unstructured":"Study to evaluate the safety and antiviral activity of remdesivir (GS-5734\u2122) in participants with severe coronavirus disease (COVID-19) - full text view - ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04292899 (accessed April 9, 2020)."},{"key":"10.1016\/j.lfs.2020.117883_bb0425","unstructured":"Adaptive COVID-19 treatment trial (ACTT) - full text view - ClinicalTrials.gov, (n.d.). Https:\/\/Clinicaltrials.Gov\/Ct2\/Show\/Nct04280705 (accessed April 9, 2020)."},{"key":"10.1016\/j.lfs.2020.117883_bb0430","doi-asserted-by":"crossref","first-page":"581","DOI":"10.3201\/eid1004.030458","article-title":"Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs","volume":"10","author":"Tan","year":"2004","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.lfs.2020.117883_bb0435","first-page":"218","article-title":"Mechanism of action of ribavirin in the treatment of chronic hepatitis C","volume":"3","author":"Te","year":"2007","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"10.1016\/j.lfs.2020.117883_bb0440","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/rmv.483","article-title":"Mechanisms of action of ribavirin against distinct viruses","volume":"16","author":"Graci","year":"2006","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.lfs.2020.117883_bb0445","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.antiviral.2011.05.006","article-title":"Depletion of GTP pool is not the predominant mechanism by which ribavirin exerts its antiviral effect on Lassa virus","volume":"91","author":"\u00d6lschl\u00e4ger","year":"2011","journal-title":"Antivir. Res."},{"key":"10.1016\/j.lfs.2020.117883_bb0450","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/srep01686","article-title":"Inhibition of novel \u03b2 coronavirus replication by a combination of interferon-\u03b12b and ribavirin","volume":"3","author":"Falzarano","year":"2013","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2020.117883_bb0455","doi-asserted-by":"crossref","first-page":"58","DOI":"10.5582\/ddt.2020.01012","article-title":"Discovering drugs to treat coronavirus disease 2019 (COVID-19)","volume":"14","author":"Dong","year":"2020","journal-title":"Drug Discoveries & Therapeutics"},{"key":"10.1016\/j.lfs.2020.117883_bb0460","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1086\/378304","article-title":"Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada","volume":"37","author":"Knowles","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.lfs.2020.117883_bb0465","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings","volume":"59","author":"Chu","year":"2004","journal-title":"Thorax"},{"key":"10.1016\/j.lfs.2020.117883_bb0470","unstructured":"Lopinavir\/Ritonavir, Ribavirin and IFN-beta combination for nCoV treatment - full text view - ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04276688 (accessed April 9, 2020)."},{"key":"10.1016\/j.lfs.2020.117883_bb0475","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.antiviral.2014.04.006","article-title":"Arbidol as a broad-spectrum antiviral: an update","volume":"107","author":"Blaising","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.lfs.2020.117883_bb0480","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02185-18","article-title":"Arbidol and other low-molecular-weight drugs that inhibit lassa and ebola viruses","volume":"93","author":"Hulseberg","year":"2019","journal-title":"J. Virol."},{"key":"10.1016\/j.lfs.2020.117883_bb0485","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1128\/JVI.02077-15","article-title":"The synthetic antiviral drug arbidol inhibits globally prevalent pathogenic viruses","volume":"90","author":"P\u00e9cheur","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.lfs.2020.117883_bb0490","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015874","article-title":"Mechanism of inhibition of enveloped virus membrane fusion by the antiviral drug arbidol","volume":"6","author":"Teissier","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2020.117883_bb0495","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1073\/pnas.1617020114","article-title":"Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol","volume":"114","author":"Kadam","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lfs.2020.117883_bb0500","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/13543784.2017.1269170","article-title":"Investigational hemagglutinin-targeted influenza virus inhibitors","volume":"26","author":"Zeng","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.lfs.2020.117883_bb0505","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.clinthera.2009.04.016","article-title":"Pharmacokinetic properties and bioequivalence of two formulations of arbidol: an open-label, single-dose, randomized-sequence, two-period crossover study in healthy chinese male volunteers","volume":"31","author":"Liu","year":"2009","journal-title":"Clin. Ther."},{"key":"10.1016\/j.lfs.2020.117883_bb0510","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1128\/AAC.02282-12","article-title":"Pharmacokinetics, metabolism, and excretion of the antiviral drug arbidol in humans","volume":"57","author":"Deng","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2020.117883_bb0515","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/jphp.12014","article-title":"Glucuronidation of the broad-spectrum antiviral drug arbidol by UGT isoforms: UGT isoforms for arbidol glucuronidation","volume":"65","author":"Song","year":"2013","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.lfs.2020.117883_bb0520","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40779-020-0233-6","article-title":"A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)","volume":"7","author":"Jin","year":"2020","journal-title":"Military Medical Research"},{"key":"10.1016\/j.lfs.2020.117883_bb0525","unstructured":"Clinical study of arbidol hydrochloride tablets in the treatment of pneumonia caused by novel coronavirus - full text view - ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04260594 (accessed April 9, 2020)."},{"key":"10.1016\/j.lfs.2020.117883_bb0530","unstructured":"Evaluating the efficacy and safety of bromhexine hydrochloride tablets combined with standard treatment\/standard treatment in patients with suspected and mild novel coronavirus pneumonia (COVID-19) - full text view - ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04273763 (accessed April 9, 2020)."},{"key":"10.1016\/j.lfs.2020.117883_bb0535","first-page":"101710","article-title":"Potential repurposing of Favipiravir in COVID-19 outbreak based on current evidence","author":"K. K.","year":"2020","journal-title":"Travel Med. Infect. Dis."},{"key":"10.1016\/j.lfs.2020.117883_bb0540","unstructured":"Dose-finding study of favipiravir in the treatment of uncomplicated influenza, ClinicalTrials.Gov. (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01068912 (accessed May 16, 2020)."},{"key":"10.1016\/j.lfs.2020.117883_bb0545","unstructured":"Phase 3 efficacy and safety study of favipiravir for treatment of uncomplicated influenza in adults - T705US316, ClinicalTrials.Gov. (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02026349 (accessed May 16, 2020)."},{"key":"10.1016\/j.lfs.2020.117883_bb0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.eng.2020.03.007","article-title":"Experimental treatment with favipiravir for COVID-19: an open-label control study","author":"Cai","year":"2020","journal-title":"Engineering"},{"key":"10.1016\/j.lfs.2020.117883_bb0555","unstructured":"Researchers find two new drugs that can effectively inhibit coronavirus, (n.d.). https:\/\/news.cgtn.com\/news\/2020-02-04\/Researchers-find-two-drugs-that-can-effectively-inhibit-coronavirus-NOFpci7NJK\/index.html (accessed May 17, 2020)."},{"key":"10.1016\/j.lfs.2020.117883_bb0560","author":"Lu"},{"key":"10.1016\/j.lfs.2020.117883_bb0565","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1089\/aid.2018.0178","article-title":"Simplification of antiretroviral treatment from darunavir\/ritonavir monotherapy to darunavir\/cobicistat monotherapy: effectiveness and safety in routine clinical practice","volume":"35","author":"Santos","year":"2019","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.lfs.2020.117883_bb0570","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/clpt.2009.228","article-title":"Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity","volume":"87","author":"Mathias","year":"2010","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"10.1016\/j.lfs.2020.117883_bb0575","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1093\/cid\/cix1150","article-title":"Oseltamivir treatment of influenza in children","volume":"66","author":"Uyeki","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.lfs.2020.117883_bb0580","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China","author":"Wang","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.lfs.2020.117883_bb0585","author":"Kongsaengdao"},{"key":"10.1016\/j.lfs.2020.117883_bb0590","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1146\/annurev.immunol.23.021704.115633","article-title":"IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors","volume":"23","author":"Liu","year":"2005","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.lfs.2020.117883_bb0595","doi-asserted-by":"crossref","first-page":"a032003","DOI":"10.1101\/cshperspect.a032003","article-title":"Interferon \u03b2 for multiple sclerosis","volume":"8","author":"Jakimovski","year":"2018","journal-title":"Cold Spring Harb Perspect Med."},{"key":"10.1016\/j.lfs.2020.117883_bb0600","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.coviro.2012.04.004","article-title":"SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon","volume":"2","author":"Totura","year":"2012","journal-title":"Current Opinion in Virology"},{"key":"10.1016\/j.lfs.2020.117883_bb0605","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1146\/annurev-immunol-032713-120231","article-title":"Interferon-stimulated genes: a complex web of host defenses","volume":"32","author":"Schneider","year":"2014","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.lfs.2020.117883_bb0610","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1473-3099(14)70920-X","article-title":"Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study","volume":"14","author":"Omrani","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.lfs.2020.117883_bb0615","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3201\/eid1002.030482","article-title":"Interferon-\u03b2 1a and SARS coronavirus replication","volume":"10","author":"Hensley","year":"2004","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.lfs.2020.117883_bb0620","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jinf.2013.09.029","article-title":"Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus","volume":"67","author":"Chan","year":"2013","journal-title":"J. Infect."},{"key":"10.1016\/j.lfs.2020.117883_bb0625","article-title":"Diagnosis and treatment of 2019 novel coronavirus infection in children: a pressing issue","author":"Shen","year":"2020","journal-title":"World J. Pediatr."},{"key":"10.1016\/j.lfs.2020.117883_bb0630","unstructured":"Efficacy and safety of IFN-\u03b12\u03b2 in the treatment of novel coronavirus patients - full text view - ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04293887 (accessed April 10, 2020)."},{"key":"10.1016\/j.lfs.2020.117883_bb0635","unstructured":"Pegylated interferon lambda treatment for COVID-19 - full text view - ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04343976 (accessed May 23, 2020)."},{"key":"10.1016\/j.lfs.2020.117883_bb0640","unstructured":"Interferon lambda therapy for COVID-19 - full text view - ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04388709 (accessed May 23, 2020)."},{"key":"10.1016\/j.lfs.2020.117883_bb0645","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/FPC.0000000000000270","article-title":"PharmGKB summary: macrolide antibiotic pathway, pharmacokinetics\/pharmacodynamics","volume":"27","author":"Fohner","year":"2017","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.lfs.2020.117883_bb0650","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1183\/09031936.00095809","article-title":"Azithromycin induces anti-viral responses in bronchial epithelial cells","volume":"36","author":"Gielen","year":"2010","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.lfs.2020.117883_bb0655","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1006\/excr.2002.5613","article-title":"Azithromycin, a lysosomotropic antibiotic, has distinct effects on fluid-phase and receptor-mediated endocytosis, but does not impair phagocytosis in J774 macrophages","volume":"281","author":"Tyteca","year":"2002","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.lfs.2020.117883_bb0660","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00394-19","article-title":"Azithromycin protects against zika virus infection by upregulating virus-induced Type I and III interferon responses","volume":"63","author":"Li","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2020.117883_bb0665","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.1857","article-title":"Clinical pharmacology perspectives on the antiviral activity of azithromycin and use in COVID-19","author":"Damle","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.lfs.2020.117883_bb0670","unstructured":"Hydroxychloroquine vs. azithromycin for hospitalized patients with suspected or confirmed COVID-19 - full text view - ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04329832 (accessed May 18, 2020)."},{"key":"10.1016\/j.lfs.2020.117883_bb0675","unstructured":"Clinical trial of combined use of hydroxychloroquine, azithromycin, and tocilizumab for the treatment of COVID-19 - full text view - ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04332094 (accessed May 18, 2020)."},{"key":"10.1016\/j.lfs.2020.117883_bb0680","unstructured":"Evaluating the efficacy of hydroxychloroquine and azithromycin to prevent hospitalization or death in persons with COVID-19 - full text view - ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04358068 (accessed May 18, 2020)."},{"key":"10.1016\/j.lfs.2020.117883_bb0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","author":"Gautret","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.lfs.2020.117883_bb0690","first-page":"C539","article-title":"Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature","volume":"299","author":"Griffin","year":"2010","journal-title":"Am. J. Phys. Cell Phys."},{"key":"10.1016\/j.lfs.2020.117883_bb0695","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01564-16","article-title":"Neurovirulent murine coronavirus JHM.SD uses cellular zinc metalloproteases for virus entry and cell-cell fusion","volume":"91","author":"Phillips","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.lfs.2020.117883_bb0700","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1111\/jdv.14345","article-title":"Doxycycline as an anti-inflammatory agent: updates in dermatology","volume":"31","author":"Henehan","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.lfs.2020.117883_bb0705","author":"Nantes University Hospital"},{"key":"10.1016\/j.lfs.2020.117883_bb0710","doi-asserted-by":"crossref","first-page":"276","DOI":"10.7164\/antibiotics.31.276","article-title":"Teichomycins, new antibiotics from Actinoplanes teichomyceticus nov. sp. I. Description of the producer strain, fermentation studies and biological properties","volume":"31","author":"Parenti","year":"1978","journal-title":"J. Antibiot."},{"key":"10.1016\/j.lfs.2020.117883_bb0715","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ijantimicag.2016.07.004","article-title":"Fighting viruses with antibiotics: an overlooked path","volume":"48","author":"Colson","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.lfs.2020.117883_bb0720","doi-asserted-by":"crossref","first-page":"9218","DOI":"10.1074\/jbc.M116.716100","article-title":"Glycopeptide antibiotics potently inhibit cathepsin l in the late endosome\/lysosome and block the entry of ebola virus, middle east respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV)","volume":"291","author":"Zhou","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lfs.2020.117883_bb0725","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0195-6701(86)90011-3","article-title":"Structure and mechanism of action of teicoplanin","volume":"7","author":"Parenti","year":"1986","journal-title":"J. Hosp. Infect."},{"key":"10.1016\/j.lfs.2020.117883_bb0730","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1128\/AAC.26.6.917","article-title":"Teicoplanin, a new antibiotic from Actinoplanes teichomyceticus nov. sp","volume":"26","author":"Somma","year":"1984","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2020.117883_bb0735","article-title":"Teicoplanin potently blocks the cell entry of 2019-nCoV","author":"Zhang","year":"2020","journal-title":"Microbiology"},{"key":"10.1016\/j.lfs.2020.117883_bb0740","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1128\/AAC.36.8.1744","article-title":"Teicoplanin metabolism in humans","volume":"36","author":"Bernareggi","year":"1992","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2020.117883_bb0745","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2165\/00003495-199040030-00007","article-title":"Teicoplanin","volume":"40","author":"Campoli-Richards","year":"1990","journal-title":"Drugs"},{"key":"10.1016\/j.lfs.2020.117883_bb0750","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1128\/AAC.03659-14","article-title":"Antiviral potential of ERK\/MAPK and PI3K\/AKT\/mTOR signaling modulation for middle east respiratory syndrome coronavirus infection as identified by temporal kinome analysis","volume":"59","author":"Kindrachuk","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.lfs.2020.117883_bb0755","author":"Gupta"},{"key":"10.1016\/j.lfs.2020.117883_bb0760","author":"Kraft"},{"key":"10.1016\/j.lfs.2020.117883_bb0765","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2020.117883_bb0770","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/1759720X16687481","article-title":"Baricitinib in rheumatoid arthritis: evidence-to-date and clinical potential","volume":"9","author":"Kuriya","year":"2017","journal-title":"Therapeutic Advances in Musculoskeletal"},{"key":"10.1016\/j.lfs.2020.117883_bb0775","unstructured":"Treatment of moderate to severe coronavirus disease (COVID-19) in hospitalized patients - full text view - ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04321993 (accessed May 19, 2020)."},{"key":"10.1016\/j.lfs.2020.117883_bb0780","unstructured":"Clinical trial to evaluate efficacy of 3 types of treatment in patients with pneumonia by COVID-19 - full text view - ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04346147 (accessed May 19, 2020)."},{"key":"10.1016\/j.lfs.2020.117883_bb0785","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s12016-016-8582-3","article-title":"The use of cyclosporine a in rheumatology: a 2016 comprehensive review","volume":"52","author":"Chighizola","year":"2017","journal-title":"Clinic Rev Allerg Immunol"},{"key":"10.1016\/j.lfs.2020.117883_bb0790","doi-asserted-by":"crossref","first-page":"953","DOI":"10.2165\/00003495-199345060-00007","article-title":"Cyclosporin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders","volume":"45","author":"Faulds","year":"1993","journal-title":"Drugs"},{"key":"10.1016\/j.lfs.2020.117883_bb0795","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1099\/vir.0.034983-0","article-title":"Cyclosporin A inhibits the replication of diverse coronaviruses","volume":"92","author":"de Wilde","year":"2011","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.lfs.2020.117883_bb0800","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.dsx.2020.04.024","article-title":"Can dapagliflozin have a protective effect against COVID-19 infection? A hypothesis","volume":"14","author":"Cure","year":"2020","journal-title":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews"},{"key":"10.1016\/j.lfs.2020.117883_bb0805","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/art.40071","article-title":"Review: cytokine storm syndrome: looking toward the precision medicine era","volume":"69","author":"Behrens","year":"2017","journal-title":"Arthritis & Rheumatology"},{"key":"10.1016\/j.lfs.2020.117883_bb0810","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/jcph.826","article-title":"Pharmacokinetic and pharmacodynamic analysis of subcutaneous tocilizumab in patients with rheumatoid arthritis from 2 randomized, controlled trials: SUMMACTA and BREVACTA: pharmacokinetic and pharmacodynamic analysis of subcutaneous","volume":"57","author":"Abdallah","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.lfs.2020.117883_bb0815","doi-asserted-by":"crossref","first-page":"10970","DOI":"10.1073\/pnas.2005615117","article-title":"Effective treatment of severe COVID-19 patients with tocilizumab","volume":"117","author":"Xu","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lfs.2020.117883_bb0820","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1007\/s00134-020-05991-x","article-title":"Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China","volume":"46","author":"Ruan","year":"2020","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.lfs.2020.117883_bb0825","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2165\/11531280-000000000-00000","article-title":"Clinical pharmacokinetics of therapeutic monoclonal antibodies","volume":"49","author":"Keizer","year":"2010","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.lfs.2020.117883_bb0830","author":"National Cancer Institute, Naples"},{"key":"10.1016\/j.lfs.2020.117883_bb0835","unstructured":"The use of tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation - full text view - ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04377750 (accessed May 20, 2020)."},{"key":"10.1016\/j.lfs.2020.117883_bb0840","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1042\/BJ20120150","article-title":"Ivermectin is a specific inhibitor of importin \u03b1\/\u03b2-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus","volume":"443","author":"Wagstaff","year":"2012","journal-title":"Biochem. J."},{"key":"10.1016\/j.lfs.2020.117883_bb0845","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104760","article-title":"The broad spectrum antiviral ivermectin targets the host nuclear transport importin \u03b1\/\u03b21 heterodimer","volume":"177","author":"Yang","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.lfs.2020.117883_bb0850","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro","volume":"178","author":"Caly","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.lfs.2020.117883_bb0855","author":"Centenario Hospital Miguel Hidalgo"},{"key":"10.1016\/j.lfs.2020.117883_bb0860","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1093\/ndt\/gfv025","article-title":"Circulating angiotensin-converting enzyme 2 activity in patients with chronic kidney disease without previous history of cardiovascular disease","volume":"30","author":"Anguiano","year":"2015","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.lfs.2020.117883_bb0865","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nature02145","article-title":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus","volume":"426","author":"Li","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2020.117883_bb0870","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.lfs.2020.117883_bb0875","unstructured":"Clinical management of severe acute respiratory infection when COVID-19 is suspected, (n.d.). https:\/\/www.who.int\/publications-detail\/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected (accessed April 10, 2020)."},{"key":"10.1016\/j.lfs.2020.117883_bb0880","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(20)30317-2","article-title":"Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury","volume":"395","author":"Russell","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2020.117883_bb0885","doi-asserted-by":"crossref","DOI":"10.1007\/s00134-020-06022-5","article-title":"Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19)","author":"Alhazzani","year":"2020","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.lfs.2020.117883_bb0890","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2020.0994","article-title":"Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China","author":"Wu","year":"2020","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.lfs.2020.117883_bb0895","article-title":"Effectiveness of glucocorticoid therapy in patients with severe novel coronavirus pneumonia: protocol of a randomized controlled trial","author":"Zhou","year":"2020","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.lfs.2020.117883_bb0900","author":"Zhou"},{"key":"10.1016\/j.lfs.2020.117883_bb0905","series-title":"The Treatment and Outcomes of Patients With COVID-19 in Hubei, China: A Multi-centered, Retrospective, Observational Study, Social Science Research Network, Rochester, NY","author":"Shang","year":"2020"},{"key":"10.1016\/j.lfs.2020.117883_bb0910","author":"C. for B.E. and Research"},{"key":"10.1016\/j.lfs.2020.117883_bb0915","doi-asserted-by":"crossref","first-page":"9S","DOI":"10.1111\/j.1537-2995.2012.03622.x","article-title":"Plasma components: properties, differences, and uses","volume":"52","author":"Benjamin","year":"2012","journal-title":"Transfusion"},{"key":"10.1016\/j.lfs.2020.117883_bb0920","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102554","article-title":"Convalescent plasma in Covid-19: possible mechanisms of action","author":"Rojas","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.lfs.2020.117883_bb0925","doi-asserted-by":"crossref","DOI":"10.1172\/JCI138745","article-title":"Deployment of convalescent plasma for the prevention and treatment of COVID-19","author":"Bloch","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.lfs.2020.117883_bb0930","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1385\/CRIAI:29:3:207","article-title":"Anti-inflammatory effect of intravenous immunoglobulin mediated through modulation of complement activation","volume":"29","author":"Lutz","year":"2005","journal-title":"Clinic Rev Allerg Immunol"},{"key":"10.1016\/j.lfs.2020.117883_bb0935","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nm836","article-title":"F(ab)\u20322-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins","volume":"9","author":"Basta","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.lfs.2020.117883_bb0940","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2004168117","article-title":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients","author":"Duan","year":"2020","journal-title":"PNAS"},{"key":"10.1016\/j.lfs.2020.117883_bb0945","doi-asserted-by":"crossref","DOI":"10.1007\/s40121-020-00295-5","article-title":"Coronavirus: update related to the current outbreak of COVID-19","author":"Gabutti","year":"2020","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.lfs.2020.117883_bb0950","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S1473-3099(20)30072-4","article-title":"Challenges of coronavirus disease 2019","volume":"20","author":"The Lancet Infectious Diseases","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.lfs.2020.117883_bb0955","article-title":"WHO launches global megatrial of the four most promising coronavirus treatments","volume":"22","author":"Kupferschmidt","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.lfs.2020.117883_bb0960","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.dsx.2020.03.011","article-title":"Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: a systematic search and a narrative review with a special reference to India and other developing countries","volume":"14","author":"Singh","year":"2020","journal-title":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews"},{"key":"10.1016\/j.lfs.2020.117883_bb0965","article-title":"Running ahead of pandemics: achieving in-advance antiviral drugs","author":"Pannu","year":"2020","journal-title":"SSRN Journal"},{"key":"10.1016\/j.lfs.2020.117883_bb0970","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13578-020-00404-4","article-title":"SARS-CoV-2 and COVID-19: the most important research questions","volume":"10","author":"Yuen","year":"2020","journal-title":"Cell Biosci"},{"key":"10.1016\/j.lfs.2020.117883_bb0975","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2020.03.007","article-title":"SARS-CoV-2 vaccines: status report","author":"Amanat","year":"2020","journal-title":"Immunity."},{"key":"10.1016\/j.lfs.2020.117883_bb0980","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3390\/diagnostics10040202","article-title":"In vitro diagnostic assays for COVID-19: recent advances and emerging trends","volume":"10","author":"Vashist","year":"2020","journal-title":"Diagnostics"},{"key":"10.1016\/j.lfs.2020.117883_bb0985","unstructured":"covexit, Professor Didier Raoult releases the results of a New Hydroxychloroquine Treatment Study on 1061 patients \u2013 COVEXIT.com, (n.d.). http:\/\/covexit.com\/professor-didier-raoult-releases-the-results-of-a-new-hydroxychloroquine-treatment-study-on-1061-patients\/ (accessed April 10, 2020)."},{"key":"10.1016\/j.lfs.2020.117883_bb0990","doi-asserted-by":"crossref","unstructured":"K. Dhama, K. Sharun, R. Tiwari, M. Dadar, Y.S. Malik, K.P. Singh, W. Chaicumpa, COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics, Human Vaccines & Immunotherapeutics. 0 (2020) 1\u20137. doi:https:\/\/doi.org\/10.1080\/21645515.2020.1735227.","DOI":"10.1080\/21645515.2020.1735227"},{"key":"10.1016\/j.lfs.2020.117883_bb0995","doi-asserted-by":"crossref","first-page":"138277","DOI":"10.1016\/j.scitotenv.2020.138277","article-title":"COVID-19: A promising cure for the global panic","volume":"725","author":"Vellingiri","year":"2020","journal-title":"Sci. Total Environ."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320520306330?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320520306330?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T19:18:00Z","timestamp":1735413480000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320520306330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":199,"alternative-id":["S0024320520306330"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2020.117883","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2020.117883","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"117883"}}